Cramer's Morning Take: Bristol Myers & Eli Lilly 11/25/24

Jim and Jeff dive into the biopharmaceutical landscape, spotlighting Bristol-Myers' groundbreaking schizophrenia drug and its investment implications. They also discuss the looming patent cliffs that could reshape earnings forecasts by 2028. The conversation veers into the financial outlook for major players like Bristol-Myers and Eli Lilly, exploring revenue potential linked to new drug approvals amidst the challenges of product development. It's an insightful take on the pharmaceutical market dynamics and investment strategies.